fourteen News

Fidia completes establishment of its operations and seeks further growth opportunities in North America

PARSIPPANY, N.J. & ABANO TERME, Italy July 07, 2014 — Fidia Pharma USA Inc., a wholly-owned subsidiary of Fidia Farmaceutici SpA, an international integrated company and recognized leader in hyaluronic acid-based products, announced today the completion of the establishment of its operations in the United States.

Effective July 2014, the company’s sales force, previously operating under the contract sales organization Interpace BioPharma, a subsidiary of PDI, Inc., successfully transitioned to Fidia Pharma USA Inc. “This represents a key milestone in establishing Fidia in the US market.” says Mr. Aldo Donati, President of Fidia Pharma USA Inc. “We have created a fully integrated strategic and operational team of over 90 employees dedicated to maximize our growing Hyalgan® franchise (Sodium hyaluronate), intra-articular injections approved for the treatment of osteoarthritis of the knee, and pursue new internal and external business development opportunities.”

Fidia Pharma USA’s national sales force coverage strengthens Fidia’s presence in the US market and constitutes a strong platform for further expansion. “We are seeking continued growth opportunities in North America, where we expect to leverage our global R&D pipeline and portfolio with the launch of new products. We are also intensifying our efforts to identify synergic licensing, co-promotion and M&A opportunities, as well as expand Fidia’s presence into Canada,” states Mr. Giorgio Foresti, CEO of Fidia Farmaceutici SpA.

About Fidia Pharma USA Inc.
Fidia Pharma USA Inc., headquartered in Parsippany, NJ, is a wholly-owned subsidiary of the multinational pharmaceutical company Fidia Farmaceutici SpA. Fidia Pharma USA is focused on establishing and expanding Fidia’s position in the US and Canada markets, while upholding the company’s mission to provide consumers with innovative products that offer quality, safety and performance. Drawing on the strengths of the parent company, Fidia Pharma USA’s product portfolio focuses primarily on therapeutic areas such as Joint Healthcare and Advanced Wound Care. For more information, please visit

About Fidia Farmaceutici SpA
Fidia Farmaceutici SpA is a multinational integrated pharma company headquartered in Abano Terme, Italy and based on extensive research on hyaluronan (GAG family) and its proprietary derivatives, with specialized technology platforms, that enable the company to produce hyaluronic acids with different molecular weights and characteristics, according to the indications designed for the finished products. Fidia Farmaceutici SpA products are marketed in over 100 countries worldwide, through fully owned subsidiaries and a comprehensive network of alliances and distributors. The company operates in diverse therapeutic areas, providing a wide array of innovative treatment options – medicinal products, medical devices, nutritional supplements and biomaterials – for application in Joint Healthcare, Advanced Wound Care, Dermatology and Aesthetics.
Fidia Farmaceutici SpA is part of P&R Holding, a chemical group operating in the manufacturing of Active Pharmaceutical Ingredients, Advanced Intermediates, and High Potency Drugs dedicated to diseases with high socio-economic relevance.

More information can be found on our corporate website

Carolyn Kong
Fidia Pharma USA Inc.
Morris Corporate Center 1 – Bldg. C
300 Interpace Parkway
Parsippany, NJ 07054
Tel. +1-973-507-5120

Our Four Leading Principles: